摘要
目的 初步评价CHOP方案联合利妥昔单抗（R-CHOP）对老年弥漫大B细胞淋巴瘤（DLBCL）的疗效及不良反应。方法 12例老年初治DLBCL患者，分别用R-CHOP方案化疗4—6疗程。结果 完全缓解（CR）8例（67％），部分缓解2例（17％），2例（17％）发生疾病进展，2年无病生存（DFS）7例（58％）。无严重及危及生命的不良反应。结论 R-CHOP方案可明显改善老年DLBCL缓解的CR率及生存期，且老年患者能耐受其产生的不良反应。
Objective To evaluate the effect and toxicity of CHOP chemotherapy plus rituximab（R-CHOP） on diffuse large-B-cell lymphoma in elderly patients. Methods Previously untreated patients with diffuse large-B-cell lymphoma, 60 to 78 years old, received four to six courses of treatment of R-CHOP. Results The rate of complete relief and partial relief was 67% and 17% respectively,while the disease in 2 patients progressed. The 2-year survival rate was 58%. The relevant toxicity was well tolerated. Conclusions R-CHOP regimen may improve the outcome and will be well tolerated in elderly patients with diffuse large-B-cell lymphoma.
出处
《实用老年医学》
CAS
2006年第4期266-268,共3页
Practical Geriatrics
